Should the drug industry work with key opinion leaders? No
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39541.731493.59 (Published 19 June 2008) Cite this as: BMJ 2008;336:1405- Giovanni A Fava, professor of clinical psychology
- 1University of Bologna, Italy
- giovanniandrea.fava{at}unibo.it
The proliferating connections between doctors and the drug industry have brought the credibility of clinical medicine to an unprecedented crisis. Corporate actions that have placed profit over public health have become regular news. High profile examples include the misrepresentation of research on rofecoxib and on the use of selective serotonin reuptake inhibitors in children. Recently, two respected scientists who work for a drug company wrote that the problem of conflict of interest “could well erode the credibility of the entire enterprise of academic medicine, if not properly and promptly addressed.”1 2
Industry objectives
The game is clear: to get as close as possible to universal prescribing of a drug by manipulating evidence and withholding data. A recent paper illustrates how selective publication of trials of antidepressants exaggerated their efficacy.3 Thirty seven of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.